Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy
Ipilimumab, a fully human monoclonal antibody that blocks cytotoxic T-lymphocyte antigen 4 (CTLA-4) to augment antitumor immune responses, was approved by the Food and Drug Administration (FDA) and the European Medicines Agency in 2011 at a dose of 3 mg per kilogram of body weight for the treatment...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2016
|
| In: |
The New England journal of medicine
Year: 2018, Jahrgang: 375, Heft: 19, Pages: 1845-1855 |
| ISSN: | 1533-4406 |
| DOI: | 10.1056/NEJMoa1611299 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1056/NEJMoa1611299 Verlag, lizenzpflichtig, Volltext: https://www.nejm.org/doi/10.1056/NEJMoa1611299 
|
| Verfasserangaben: | A.M.M. Eggermont, V. Chiarion-Sileni, J.-J. Grob, R. Dummer, J.D. Wolchok, H. Schmidt, O. Hamid, C. Robert, P.A. Ascierto, J.M. Richards, C. Lebbé, V. Ferraresi, M. Smylie, J.S. Weber, M. Maio, L. Bastholt, L. Mortier, L. Thomas, S. Tahir, A. Hauschild, J.C. Hassel, F.S. Hodi, C. Taitt, V. de Pril, G. de Schaetzen, S. Suciu, and A. Testori |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1699967237 | ||
| 003 | DE-627 | ||
| 005 | 20230831095341.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200605r20162018xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1056/NEJMoa1611299 |2 doi | |
| 035 | |a (DE-627)1699967237 | ||
| 035 | |a (DE-599)KXP1699967237 | ||
| 035 | |a (OCoLC)1341336594 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Eggermont, Alexander |e VerfasserIn |0 (DE-588)173227821 |0 (DE-627)698147405 |0 (DE-576)134077482 |4 aut | |
| 245 | 1 | 0 | |a Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy |c A.M.M. Eggermont, V. Chiarion-Sileni, J.-J. Grob, R. Dummer, J.D. Wolchok, H. Schmidt, O. Hamid, C. Robert, P.A. Ascierto, J.M. Richards, C. Lebbé, V. Ferraresi, M. Smylie, J.S. Weber, M. Maio, L. Bastholt, L. Mortier, L. Thomas, S. Tahir, A. Hauschild, J.C. Hassel, F.S. Hodi, C. Taitt, V. de Pril, G. de Schaetzen, S. Suciu, and A. Testori |
| 264 | 1 | |c 2016 | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Published on October 8, 2016, and updated on November 9, 2018 | ||
| 500 | |a Gesehen am 05.06.2020 | ||
| 520 | |a Ipilimumab, a fully human monoclonal antibody that blocks cytotoxic T-lymphocyte antigen 4 (CTLA-4) to augment antitumor immune responses, was approved by the Food and Drug Administration (FDA) and the European Medicines Agency in 2011 at a dose of 3 mg per kilogram of body weight for the treatment of advanced melanoma.1,2 On the basis of data from a phase 2 trial that indicated the potential for a dose of 10 mg per kilogram to have higher efficacy than the dose of 0.3 mg or 3 mg per kilogram in patients with advanced melanoma, although at a cost of more . . . | ||
| 534 | |c 2018 | ||
| 700 | 1 | |a Chiarion-Sileni, Vanna |e VerfasserIn |4 aut | |
| 700 | 1 | |a Grob, Jean-Jacques |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dummer, Reinhard |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wolchok, Jedd D. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schmidt, Henrik |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hamid, Omid |e VerfasserIn |0 (DE-588)1300402733 |0 (DE-627)1858210348 |4 aut | |
| 700 | 1 | |a Robert, Caroline |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ascierto, Paolo A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Richards, Jon M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lebbé, Céleste |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ferraresi, Virginia |e VerfasserIn |4 aut | |
| 700 | 1 | |a Smylie, Michael |e VerfasserIn |4 aut | |
| 700 | 1 | |a Weber, Jeffrey S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Maio, Michele |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bastholt, Lars |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mortier, Laurent |e VerfasserIn |4 aut | |
| 700 | 1 | |a Thomas, Luc |e VerfasserIn |4 aut | |
| 700 | 1 | |a Tahir, Saad |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hauschild, Axel |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hassel, Jessica C. |d 1975- |e VerfasserIn |0 (DE-588)129790702 |0 (DE-627)480399069 |0 (DE-576)29783715X |4 aut | |
| 700 | 1 | |a Hodi, F. Stephen |e VerfasserIn |4 aut | |
| 700 | 1 | |a Taitt, Corina |e VerfasserIn |4 aut | |
| 700 | 1 | |a de Pril, Veerle |e VerfasserIn |4 aut | |
| 700 | 1 | |a de Schaetzen, Gaetan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Suciu, Stefan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Testori, Alessandro |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The New England journal of medicine |d Waltham, Mass. : MMS, 1928 |g 375(2016), 19, Seite 1845-1855 |h Online-Ressource |w (DE-627)266889484 |w (DE-600)1468837-2 |w (DE-576)075962454 |x 1533-4406 |7 nnas |a Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy |
| 773 | 1 | 8 | |g volume:375 |g year:2016 |g number:19 |g pages:1845-1855 |g extent:11 |a Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy |
| 856 | 4 | 0 | |u https://doi.org/10.1056/NEJMoa1611299 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.nejm.org/doi/10.1056/NEJMoa1611299 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200605 | ||
| 993 | |a Article | ||
| 994 | |a 2016 | ||
| 998 | |g 129790702 |a Hassel, Jessica C. |m 129790702:Hassel, Jessica C. |d 910000 |d 911300 |e 910000PH129790702 |e 911300PH129790702 |k 0/910000/ |k 1/910000/911300/ |p 21 | ||
| 999 | |a KXP-PPN1699967237 |e 3683468831 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"title":"Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy","title_sort":"Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"language":["eng"],"note":["Published on October 8, 2016, and updated on November 9, 2018","Gesehen am 05.06.2020"],"origin":[{"dateIssuedDisp":"2016","dateIssuedKey":"2016"}],"relHost":[{"id":{"zdb":["1468837-2"],"issn":["1533-4406"],"eki":["266889484"]},"part":{"extent":"11","text":"375(2016), 19, Seite 1845-1855","issue":"19","pages":"1845-1855","volume":"375","year":"2016"},"corporate":[{"display":"Massachusetts Medical Society","role":"isb"}],"name":{"displayForm":["Massachusetts Medical Society"]},"pubHistory":["198.1928 -"],"titleAlt":[{"title":"NEJM"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"language":["eng"],"note":["Gesehen am 04.08.25"],"title":[{"title_sort":"New England journal of medicine","title":"The New England journal of medicine","subtitle":"NEJM"}],"origin":[{"publisher":"MMS ; MMS","dateIssuedKey":"1928","dateIssuedDisp":"1928-","publisherPlace":"Waltham, Mass. ; Boston, Mass."}],"disp":"Prolonged survival in stage III melanoma with ipilimumab adjuvant therapyThe New England journal of medicine","physDesc":[{"extent":"Online-Ressource"}],"recId":"266889484"}],"person":[{"family":"Eggermont","given":"Alexander","role":"aut","display":"Eggermont, Alexander"},{"given":"Vanna","role":"aut","family":"Chiarion-Sileni","display":"Chiarion-Sileni, Vanna"},{"role":"aut","given":"Jean-Jacques","family":"Grob","display":"Grob, Jean-Jacques"},{"display":"Dummer, Reinhard","family":"Dummer","role":"aut","given":"Reinhard"},{"display":"Wolchok, Jedd D.","family":"Wolchok","role":"aut","given":"Jedd D."},{"family":"Schmidt","role":"aut","given":"Henrik","display":"Schmidt, Henrik"},{"role":"aut","given":"Omid","family":"Hamid","display":"Hamid, Omid"},{"display":"Robert, Caroline","family":"Robert","role":"aut","given":"Caroline"},{"family":"Ascierto","role":"aut","given":"Paolo A.","display":"Ascierto, Paolo A."},{"family":"Richards","role":"aut","given":"Jon M.","display":"Richards, Jon M."},{"display":"Lebbé, Céleste","role":"aut","given":"Céleste","family":"Lebbé"},{"display":"Ferraresi, Virginia","family":"Ferraresi","given":"Virginia","role":"aut"},{"display":"Smylie, Michael","family":"Smylie","given":"Michael","role":"aut"},{"role":"aut","given":"Jeffrey S.","family":"Weber","display":"Weber, Jeffrey S."},{"display":"Maio, Michele","role":"aut","given":"Michele","family":"Maio"},{"family":"Bastholt","role":"aut","given":"Lars","display":"Bastholt, Lars"},{"display":"Mortier, Laurent","family":"Mortier","given":"Laurent","role":"aut"},{"display":"Thomas, Luc","given":"Luc","role":"aut","family":"Thomas"},{"display":"Tahir, Saad","family":"Tahir","role":"aut","given":"Saad"},{"role":"aut","given":"Axel","family":"Hauschild","display":"Hauschild, Axel"},{"role":"aut","given":"Jessica C.","family":"Hassel","display":"Hassel, Jessica C."},{"display":"Hodi, F. Stephen","role":"aut","given":"F. Stephen","family":"Hodi"},{"display":"Taitt, Corina","family":"Taitt","given":"Corina","role":"aut"},{"display":"de Pril, Veerle","family":"de Pril","role":"aut","given":"Veerle"},{"family":"de Schaetzen","role":"aut","given":"Gaetan","display":"de Schaetzen, Gaetan"},{"display":"Suciu, Stefan","given":"Stefan","role":"aut","family":"Suciu"},{"family":"Testori","role":"aut","given":"Alessandro","display":"Testori, Alessandro"}],"recId":"1699967237","physDesc":[{"extent":"11 S."}],"id":{"doi":["10.1056/NEJMoa1611299"],"eki":["1699967237"]},"name":{"displayForm":["A.M.M. Eggermont, V. Chiarion-Sileni, J.-J. Grob, R. Dummer, J.D. Wolchok, H. Schmidt, O. Hamid, C. Robert, P.A. Ascierto, J.M. Richards, C. Lebbé, V. Ferraresi, M. Smylie, J.S. Weber, M. Maio, L. Bastholt, L. Mortier, L. Thomas, S. Tahir, A. Hauschild, J.C. Hassel, F.S. Hodi, C. Taitt, V. de Pril, G. de Schaetzen, S. Suciu, and A. Testori"]}} | ||
| SRT | |a EGGERMONTAPROLONGEDS2016 | ||